Long Overdue Update...
- Dec 20, 2015
- 1 min read
Updated: May 13, 2022
Hello friends. Thank you for visiting. Please forgive my woeful lack of attention to this site!
As we all know, COVID has had a tremendous impact on performing artists, not to mention the industry as a whole. We seem to finally be emerging from the deepest depths of that situation, however, it remains fluid. We'll just have to go with the proverbial flow. Be safe out there, and please be considerate of your fellow audience members. You definitely don't want to end up on Patti LuPone's bad side!
I've gotten back to singing around NYC, most recently for Phil Geoffrey Bond's Sondheim Unplugged series at 54 Below. If you're a Sondheim fan, it is absolutely required viewing. Phil's knowledge of the Sondheim canon is nothing short of encyclopedic. You can also pick up the first two volumes
I'm also looking forward to getting back to Scott Siegel's terrific Frank Sinatra tributes as well as his Broadway's Greatest Hits series. Scott is a terrific host who really cares about showcasing the best singers around town, presenting fan favorites and lesser known gems, alike.
Genuinely impressed by the depth of this article!
Tirzepatide, the dual GIP/GLP-1 receptor agonist marketed as Mounjaro, has pushed the boundaries even further. Clinical trial data shows average weight reductions exceeding 20% of body weight in some cohorts, numbers that were previously only associated with bariatric surgery. This has sparked enormous interest in peptide therapy as a primary intervention for metabolic syndrome, not just as an adjunct. The conversation has shifted from 'can medication help with weight loss' to 'how do we best integrate these powerful incretin-based tools into comprehensive metabolic health programs.' Clinicians are now routinely discussing semaglutide dosing titration, injection technique, and long-term maintenance strategies as core components of obesity medicine.
What's particularly notable is the growing body…